Health
Study shows benefits of early anticlotting therapy in moderate COVID-19: International RAPID Trial could contribute to clinical practice – Science Daily
New research shows that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with…
COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly in the lungs, and is believed to contribute to progression to severe disease and death. New trial results show that administering a full dose of a standard…
Continue Reading
-
General12 hours agoVictorian school teacher charged with soliciting child abuse material
-
Business21 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business23 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
Business20 hours agoHere’s what analysts expect for the BHP share price in the coming year